menu
    • menu

    Company profile for Pardes Biosciences

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world’s most pressing public health challenges. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. The company’s lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections. P...
    Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the world’s most pressing public health challenges. Pardes leverages structure-based drug design and a tunable, reversible covalent chemistry platform for novel drug discovery. The company’s lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections. PBI-0451 is designed to inhibit the coronavirus main protease, an essential protein for SARS-CoV-2. This protease is highly similar across all coronaviruses, including emerging coronavirus variants.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Pardes BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Berkeley, CA 94710
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pardesbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pardesbio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pardes Biosciences Announces Closing of Tender Offer
    Pardes Biosciences Announces Closing of Tender Offer

    31 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/31/2735239/0/en/Pardes-Biosciences-Announces-Closing-of-Tender-Offer.html

    GLOBENEWSWIRE
    31 Aug 2023
    Share Share
    MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Pardes
    MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Pardes

    28 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230828141123/en

    BUSINESSWIRE
    28 Aug 2023
    Share Share
    Pardes changes hands (sort of) in wake of COVID-19 trial fail
    Pardes changes hands (sort of) in wake of COVID-19 trial fail

    17 Jul 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pardes-changes-hands-sort-wake-covid-trial-fail

    James Waldron FIERCE BIOTECH
    17 Jul 2023
    Share Share
    Pardes Bio to suspend COVID-19 drug development after mid-stage trial fails
    Pardes Bio to suspend COVID-19 drug development after mid-stage trial fails

    04 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/pardes-biosciences-suspend-covid-19-drug-development-after-mid-stage-trial-fails-2023-04-03/

    REUTERS
    04 Apr 2023
    Share Share
    Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
    Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

    14 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/14/2627160/0/en/Pardes-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    14 Mar 2023
    Share Share
    Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
    Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

    01 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/01/2599479/0/en/Pardes-Biosciences-to-Present-at-SVB-Securities-Global-Biopharma-Conference.html

    GLOBENEWSWIRE
    01 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search